Prevention of Epilepsy by Reducing Neonatal Encephalopathy (PREVENT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04054453 |
Recruitment Status :
Recruiting
First Posted : August 13, 2019
Last Update Posted : June 5, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The aim of the study is to examine if a pragmatic, evidenced based and generalisable intrapartum care bundle involving birth companions and empowering mothers will reduce birth injury-related epilepsy at 18 months of age in India.
The care bundle will have four key elements (interventions): (1) birth companion providing constant 1:1 care during labour and early perinatal period; (2) fetal surveillance during active labour by a nurse or midwife using a graphic display Doppler; (3) labour management by an electronic partogram with an 'alert' and 'nag' feature based on the current WHO guidelines; (4) brain oriented early newborn care with resuscitation where indicated.
The care bundle will be evaluated using a prospective interrupted time series design, recruiting 80,000 women delivering in one of the three participating centres in south India, over two years. Accurate baseline data will be collected during the first year and the optimised care bundle will be introduced during the second year. All full term newborn infants admitted to the neonatal unit with perinatal brain injury during both periods, will have detailed assessments including video electroencephalography, and magnetic resonance imaging, and will be followed up until 18 months of age.
Primary outcome is the number of infants with epilepsy (categorised per current ILAE guidelines) at 18 months of age expressed as per 1000 term livebirths. The investigators will use a segmented logistic regression to divide the time series into pre- and post-intervention segments, with the intervention date as the intersection between segments. The difference in the two segments will be quantified using the level (step change) and slope (trend change). The total duration of the study is four years including 24 months of recruitment and 18 months of follow-up.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Neonatal Encephalopathy Epilepsy Newborn Morbidity | Combination Product: Intra-partum care bundle invoking 4 elements | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 2000 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | Interrupted Time Series Evaluation |
Masking: | Single (Outcomes Assessor) |
Masking Description: | Magnetic resonance biomarkers will be quantified masked to the interventional group |
Primary Purpose: | Prevention |
Official Title: | Prevention of Epilepsy by Reducing Neonatal Encephalopathy |
Actual Study Start Date : | March 1, 2020 |
Estimated Primary Completion Date : | August 1, 2023 |
Estimated Study Completion Date : | October 30, 2023 |

Arm | Intervention/treatment |
---|---|
No Intervention: Pre-intervention
Baseline data on neonatal encephalopathy and epilepsy before the introduction of the care bundle
|
|
Experimental: Post-intervention
Baseline data on neonatal encephalopathy and epilepsy after the introduction of the care bundle
|
Combination Product: Intra-partum care bundle invoking 4 elements
Care bundle involving all the 4 elements
Other Names:
|
- Epilepsy [ Time Frame: 18 months of age ]Two of more unprovoked seizures at least 24 hours apart
- Neonatal encephalopathy [ Time Frame: 24 hours of birth ]Moderate or severe neonatal encephalopathy
- Neonatal Seizures [ Time Frame: 1 month of age ]Definite or probable seizures as per ILAE classification
- Thalamic N-aspartate levels [ Time Frame: 2 weeks of age ]Proton MR spectroscopy thalamic NAA
- Brain injury on conventional MR imaging [ Time Frame: 2 weeks of age ]Significant basal ganglia, cortical or white matter injury

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years to 50 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All pregnant women delivering at 36 weeks or later
Exclusion Criteria:
- Premature deliveries

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04054453
Contact: Sudhin Thayyil, MD, PhD | 00447912888700 | s.thayyil@imperial.ac.uk | |
Contact: Stuti Pant, MSc |
India | |
Institute of Obstetrics and Gynaecology | Not yet recruiting |
Chennai, TamilNadu, India | |
Contact: Shobha K, MD | |
Contact: Geetha Mahadevan, MD | |
Bangalore Medical College | Recruiting |
Bangalore, India | |
Contact: Savitha Chandraih, MD | |
Calicut Medical College | Recruiting |
Calicut, India | |
Contact: Mini Chenicheri, MD | |
Principal Investigator: Mini Chenicheri, MD | |
Sub-Investigator: Noorul Amin, MD | |
Sub-Investigator: Salah Basheer, MD | |
Sub-Investigator: Krishna Kumar, MD | |
United Kingdom | |
Sudhin Thayyil | Active, not recruiting |
London, United Kingdom |
Responsible Party: | Thayyil, Sudhin |
ClinicalTrials.gov Identifier: | NCT04054453 |
Other Study ID Numbers: |
NIHR200144 |
First Posted: | August 13, 2019 Key Record Dates |
Last Update Posted: | June 5, 2020 |
Last Verified: | June 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases |